Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2750
Single User License Price INR 195195
Corporate User License Price USD 4500
Corporate User License Price INR 319410
Site License Price USD 3500
Site License Price INR 248430
Request a Quote

Report Title

Global Human Insulin Market 2018-2024

Quote Request for License Type
License Type Price  
Single User License USD 2750
Site License USD 3500
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Human Insulin Market 2018-2024


Quote Request for License Type
License Type Price  
Single User License USD 2750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Human Insulin Market 2018-2024

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Human Insulin Market 2018-2024



Executive Summary

Global Human Insulin Market-Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Insulin is a peptide hormone that helps in controlling the absorption of fat and carbohydrate in the body. The human insulin market is anticipated to grow at a robust CAGR during the forecast period due to a high incidence rate of diabetes, globally.

The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin.

Market Analysis: The Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 2017-2023. The human insulin market is analyzed based on three segments-top insulin brands, product types, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global human insulin market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth.

Product Analysis: Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market.

Top Insulin Brands: Lantus is the major insulin drug in the market. Due to the loss of patents, the drug has got competition in the form of biosimilar by name Basaglar from Eli Lilly. After the loss of share for its biosimilar counterpart, the drug lost its value for its follow-up drug Toujeo. Since the launch of Toujeo in April 2015, the company has been switching over as many patients as possible to the newer drug to fill the sales gap caused by the reduced revenue of Lantus.

Key Players: Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.

Competitive Analysis: Regardless of the size of the total market, it is chiefly dominated by Novo Nordisk, Sanofi, and Eli Lilly. These firms function globally either independently or through subsidiaries and distributors. The insulin products of Novo Nordisk are sold in 111 countries along with 101 countries for Sanofi's insulin products and 94 countries for Eli Lilly's insulin products. Especially in higher income countries of Western Europe, nearly 55% of insulin products are sold by these major manufacturers. Moreover, in 2012, they occupied 88.7% of share in the global insulin market. However, there are many small companies involved in the production and sales of insulin products. Other major companies in the market are Wockhardt, Biocon, Julphar, Oramed, GSK, and SemBioSys Genetics Inc.

Benefits: The report provides complete details about the usage and adoption rate of human insulin in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Table of Contents

1 Industry Outlook 8

1.1 Industry Overview 8

1.2 Total Addressable Market 8

1.3 Industry Trends 10

2 Report Outline 11

2.1 Report Scope 11

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Segmented Addressable Market (SAM) 13

3.2.1 Trends of Human Insulin market 14

3.3 Related Markets 15

3.3.1 Oncology (Cancer) Drugs 15

3.3.2 Active pharmaceutical ingredients (APIs) 16

3.3.3 Over the counter drugs (OTC) 16

3.3.4 Diabetes Drugs 17

4 Market Outline 18

4.1 Pipeline products 18

4.2 Market Segmentation 18

4.3 Porter 5(Five) Forces 19

4.4 PEST Analysis 20

5 Market Characteristics 21

5.1 Market Dynamics 22

5.1.1 Drivers 22

5.1.1.1 Increasing Aging Population 22

5.1.1.2 Increasing People Suffering with Diabetes 24

5.1.2 Opportunities 24

5.1.2.1 Increase healthcare spending 24

5.1.2.2 Patent Expiry for Blockbuster Drugs 25

5.1.3 Restraints 25

5.1.3.1 Complex regulatory process 25

5.1.3.2 High cost of insulin 25

5.1.4 DRO-Impact Analysis 27

5.1.5 Key Stakeholders 28

6 Insulin Types: Market Size and Analysis 29

6.1 Overview 29

6.2 Lantus 29

6.3 Humulin 29

6.4 Levemir 30

6.5 Humalog 30

6.6 NovoLog/NovoRapid 30

6.7 Tresiba 31

6.8 Basaglar/ Abasaglar 31

6.9 Toujeo 31

6.10 Apidra 32

Company: Sanofi 32

7 Types: Market Size and Analysis 33

7.1 Overview 33

7.2 Modern Insulin 34

7.2.1 Rapid Acting Insulin Analogs 34

7.2.2 Premixed analogue insulins 34

7.2.3 Long-acting insulin 34

7.3 Traditional Human Insulin 35

7.3.1 Regular Human Insulin 35

7.3.2 NPH Human Insulin 36

7.3.3 Pre-Mixed Insulin 36

8 Regions: Market Size and Analysis 37

8.1 Overview 37

8.2 North America 39

8.2.1 Overview 39

8.2.2 United States 40

8.2.3 Canada 41

8.3 Europe 41

8.3.1 Overview 41

8.3.2 United Kingdom 42

8.3.3 Germany 42

8.4 APAC 43

8.4.1 Overview 43

8.4.2 India 43

8.4.3 China 44

8.4.4 Japan 44

8.5 Rest of the World 45

8.5.1 Overview 45

8.5.2 Middle East and Africa 46

8.5.3 Brazil 46

9 Competitive Landscape 47

10 Vendor Profiles 50

10.1 Novo Nordisk A/S 50

10.1.1 Overview 50

10.1.2 Geographic Revenue 52

10.1.3 Business Focus 52

10.1.4 SWOT Analysis 53

10.1.5 Business Strategy 53

10.2 Sanofi 54

10.2.1 Overview 54

10.2.2 Geographic Revenue 57

10.2.3 Business Focus 57

10.2.4 SWOT Analysis 58

10.2.5 Business Strategy 58

10.3 Eli Lilly & Company Ltd 59

10.3.1 Overview 59

10.3.2 Business Focus 62

10.3.3 SWOT Analysis 63

10.3.4 Business Strategies 63

10.4 Astra Zenca PLC. 64

10.4.1 Overview 64

10.4.2 Geographic Presence 68

10.4.3 Business Focus 68

10.4.4 SWOT Analysis 69

10.4.5 Business Strategy 69

11 Companies to Watch For 70

11.1 GlaxoSmithKline plc 70

11.1.1 Overview 70

11.2 Julphar Gulf Pharmaceutical Industries. 71

11.2.1 Overview 71

11.2.2 Highlights 72

11.3 Biocon Ltd 72

11.3.1 Overview 72

11.4 Wockhardt 74

11.4.1 Overview 74

11.4.2 Highlights 74

11.5 Oramed 74

11.5.1 Overview 74

11.5.2 Highlights 75

11.6 SemBioSys Genetics Inc. 75

11.6.1 Overview 75

Annexure 76

Abbreviations 76

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL HUMAN INSULIN MARKET 12

CHART 2 PERCENTAGE OF DIABETICS UNDIAGNOSED IN WORLD REGIONS IN 2017 13

CHART 3 GLOBAL HUMAN INSULIN MARKET REVENUE, 2017-2024 (USD MILLION) 15

CHART 4 SEGMENTATION OF GLOBAL HUMAN INSULIN MARKET 18

CHART 5 PORTER 5 FORCES OF HUMAN INSULIN MARKET 19

CHART 6 PEST ANALYSIS OF HUMAN INSULIN MARKET 20

CHART 7 MARKET DYNAMICS-DRO ANALYSIS 22

CHART 8 AGEING DEMOGRAPHIC GROWTH 23

CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 24

CHART 10 INFLATION IN THE INSULIN PRICES PER VIAL (USD ) 26

CHART 11 DRO-IMPACT ANALYSIS OF GLOBAL HUMAN INSULIN MARKET 27

CHART 12 KEY STAKEHOLDERS 28

CHART 13 HUMAN INSULIN MARKET BY TYPES SEGMENTATION, 2017 (USD MILLION) 33

CHART 14 MODERN HUMAN INSULIN MARKET BY TYPES SEGMENTATION, 2017 (USD MILLION) 34

CHART 15 HUMAN INSULIN MARKET BY TYPES SEGMENTATION, 2017 (USD MILLION) 36

CHART 16 NUMBER OF DIABETICS WORLDWIDE IN 2017, BY REGION (IN MILLIONS) 38

CHART 17 HUMAN INSULIN MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 38

CHART 18 HUMAN INSULIN MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 39

CHART 19 HUMAN INSULIN MARKET REVENUE IN THE EUROPE REGION, 2017-2023 (USD MILLION) 41

CHART 20 HUMAN INSULIN MARKET REVENUE IN THE APAC REGION, 2017-2023 (USD MILLION) 44

CHART 21 HUMAN INSULIN MARKET REVENUE IN REST OF THE WORLD, 2017-2023 (USD MILLION) 45

CHART 22 MODERN INSULIN MARKET SHARE 2017 (%SHARE) 48

CHART 23 NOVO NORDISK A/S: OVERVIEW SNAPSHOT 51

CHART 24 NOVO NORDISK A/S: SEGMENTATION 51

CHART 25 NOVO NORDISK A/S: GEOGRAPHIC REVENUE 52

CHART 26 NOVO NORDISK A/S: SWOT ANALYSIS 53

CHART 27 SANOFI SA: OVERVIEW SNAPSHOT 55

CHART 28 SANOFI SA: SEGMENTATION 56

CHART 29 SANOFI SA: GEOGRAPHIC REVENUE 57

CHART 30 SANOFI SA: SWOT ANALYSIS 58

CHART 31 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 60

CHART 32 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 61

CHART 33 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 62

CHART 34 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 63

CHART 35 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT 65

CHART 36 ASTRA ZENCA PLC: BUSINESS UNITS 67

CHART 37 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE 68

CHART 38 ASTRA ZENCA PLC: SWOT ANALYSIS 69

Tables

TABLE 1 HUMAN INSULIN MARKET REVENUE BY TYPES, 2017-2024 (USD MILLION) 33

TABLE 2 HUMAN INSULIN MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 39

TABLE 3 NOVO NORDISK A/S: PRODUCT OFFERINGS 50

TABLE 4 NOVO NORDISK A/S: RECENT DEVELOPMENTS 50

TABLE 5 SANOFI: OFFERINGS 54

TABLE 6 SANOFI: RECENT DEVELOPMENTS 55

TABLE 7 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 59

TABLE 8 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 59

TABLE 9 ASTRA ZENCA PLC: OFFERINGS 64

TABLE 10 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 64

TABLE 11 GLAXOSMITHKLINE PLC.: OVERVIEW 70

TABLE 12 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 70

TABLE 13 JULPHAR GULF PHARMACEUTICAL INDUSTRIES: OVERVIEW 72

TABLE 14 BIOCON LTD: OVERVIEW 73

TABLE 15 BIOCON LTD: RECENT DEVELOPMENTS 73

TABLE 16 SOLUBLE SYSTEMS LLC: OVERVIEW 74

TABLE 17 ORAMED: OVERVIEW 75

TABLE 18 SEMBIOSYS GENETICS INC.: RECENT DEVELOPMENTS 75

?

Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person